医学
药效学
药代动力学
内科学
肿瘤科
药理学
外显子
肺
肺癌
遗传学
基因
生物
作者
Noboru Yamamoto,Frans Opdam,M. Barve,Hanjun Tu,Yi Wu,L. Schroeter,B. Sadrolhefazi,J. Serra,Kiyotaka Yoh,J. Heymach
标识
DOI:10.1016/j.jtho.2023.09.209
摘要
There is an unmet need for effective TKIs against HER2 mutations in solid tumors, especially NSCLC. BI 1810631 is a highly potent and selective HER2 TKI that covalently binds to both wild-type and mutated HER2 receptors, including exon 20 insertions (ex20ins), while sparing EGFR. Beamion Lung 1 is an ongoing Phase Ia/Ib study to determine the safety, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary efficacy of BI 1810631 in patients with HER2 aberration-positive solid tumors (NCT04886804).
科研通智能强力驱动
Strongly Powered by AbleSci AI